Leerink Partnrs Issues Negative Outlook for Moderna Earnings

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Analysts at Leerink Partnrs decreased their FY2024 earnings per share estimates for Moderna in a report issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($9.61) per share for the year, down from their previous forecast of ($9.50). The consensus estimate for Moderna's current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna's Q4 2024 earnings at ($3.28) EPS, Q1 2025 earnings at ($2.58) EPS, Q2 2025 earnings at ($2.56) EPS, Q3 2025 earnings at ($2.55) EPS, FY2025 earnings at ($10.28) EPS, FY2026 earnings at ($7.73) EPS and FY2027 earnings at ($4.13) EPS.

Other research analysts have also issued research reports about the stock. Hsbc Global Res raised shares of Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Royal Bank of Canada reissued a "sector perform" rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Bank of America reissued an "underperform" rating and issued a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. Piper Sandler reaffirmed an "overweight" rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Wolfe Research assumed coverage on Moderna in a research note on Friday, November 15th. They issued an "underperform" rating and a $40.00 target price for the company. Four investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $75.58.

Moderna Trading Down 2.9 %

MRNA traded down $1.01 during midday trading on Thursday, reaching $33.76. 7,323,516 shares of the company were exchanged, compared to its average volume of 12,449,448. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock has a market capitalization of $12.99 billion, a P/E ratio of -5.80 and a beta of 1.60. The stock's 50-day simple moving average is $41.11 and its 200 day simple moving average is $67.32. Moderna has a one year low of $31.94 and a one year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.39) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna in the second quarter valued at $26,000. MassMutual Private Wealth & Trust FSB lifted its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. Blue Trust Inc. grew its position in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock valued at $49,000 after acquiring an additional 574 shares during the period. Larson Financial Group LLC grew its position in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the period. Finally, Rakuten Securities Inc. increased its stake in shares of Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock worth $63,000 after purchasing an additional 778 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.20% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.